Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's podcast edition of Scrip's Five Must-Know Things: US industry warns over pricing; a setback for another gene therapy; a Phase II disappointment for Novartis; Actemra shortages cause CAR-T worries; and Sweden's Sobi set to go private. 

Scrip Five Must Know Things
audio catch-up on the week's key biopharma insights

More from Drug Pricing

More from Scrip